OM1 Aspen

Prospective and retrospective study automation platform and evidence generation solution

Request a meeting

Rethink Your Approach to Patient Registries

Regulatory & market pressures demand faster, more flexible evidence

Traditional methods deliver the same results and limitations.

  • Delayed decision making and market access 
  • High costs and long timelines 
  • Gaps in regulatory and safety evidence 
  • Weakened market differentiation
  • Siloed and inflexible data collection

 

Automation changes everything.

  • Accelerate timelines and drastically reduce costs
  • Enable greater patient diversity and reduce bias
  • Consistently meet regulatory requirements for submission of RWD
  • Collect publication-ready RWD – long-term, at scale
  • Support continuous insight generation for evolving research needs

Meet OM1 Aspen

Our AI powered platform simplifies RWD collection, from reaching hard-to-find patients to scaling evidence generation at unprecedented levels. OM1’s experienced team provides end-to-end study execution, from expert study design and scientific oversight, to site and patient recruitment, and data acquisition and analysis.

Put Aspen to use today

  Click the hand icon to explore OM1 Aspen.

One solution that grows with your needs

From hypothesis generation to regulatory submission, OM1 Aspen enables life sciences organizations to automate real-world data collection and grow evergreening data networks that fuel a variety of needs.

  • Pragmatic trials & hybrid studies
  • Patient finding & site selection
  • Protocol feasibility
  • External control arms & comparator arms
  • Safety surveillance & long-term follow-up
  • Regulatory submissions
  • Market sizing
  • Post-marketing commitments
  • Registries & natural history studies

How we can help

Revolutionize your clinical research
  • Achieve unparalleled cost savings benefits
    The cost of developing new treatments is becoming increasingly expensive – and the pressure for ClinOps teams to reduce costs has never been greater. OM1’s solutions dramatically improve cost efficiency compared to traditional data collection methods.
  • Reduce site and patient burden
    Automatic prospective collection of data increases patient numbers and follow-up, while minimizing burden on sites with fewer manual tasks.
  • Enhance diversity 
    With wider site participation and broader patient populations, results are more generalizable and individualized.
Generate high-quality data to meet regulatory needs and conduct long-term follow-up
  • Meet the high bar for generating RWE for regulatory
    Fit-for-purpose, transparent, and traceable real-world data meet the high-quality, auditable data requirements for regulatory evidence.
  • Minimize the risk of loss to follow-up
    Patient consent paired with automation allows for additional prospective data collection, increasing patient numbers and follow-up for deeper, actionable insights.
  • Generate complementary evidence to fill gaps
    Build external control arms to mirror clinical trial patients or other real-world studies to demonstrate generalizability and to fill evidence gaps needed for regulatory decision making
Drive evidence-based medicine forward with rapid, digitized data collection and automated registries
  • Harness actionable insights to inform program strategy
    Leverage robust, clinically deep data to support your program strategy and accelerate Medical Affairs’ position as a strategic pillar in your organization.
  • Demonstrate patient value in real-world settings
    Bridge the insight gap. Analyze, disseminate, and communicate real-world insights to optimize experiences for patients and physicians.
  • Generate robust real-world data to assess outcomes, evaluate
    effectiveness and understand patient journeys
    Create automated, flexible registries for answering different research questions, engaging with HCPs and patients, and fueling publications.
Break data silos to unlock a continuous stream of RWE for your evolving organizational needs
  • Achieve a better understanding of patient journeys, clinical endpoints, and outcomes with direct and linked data
    Fill in the gaps with by linking additional data such as hard-to-find quality specialty data, patient reported outcomes (PROs), images, and labs.

Thought Leader in Registries

OM1 experts have been leading best practices in registries and observational studies for decades, including the AHRQ Registries for Evaluating Patient Outcomes: A User’s Guide, now in it’s 4th edition.

 

Changing the Research Paradigm

Study designs that use RWD offer a potential tool for the efficient generation of RWE to inform regulatory decision-making. Read: Using real-world evidence to support a changing paradigm for cancer screening: A commentary

Demonstrating Effectiveness

OM1 Aspen supports large-scale comparative effectiveness and outcomes studies.  Read about our largest study: Mammographic Screening in Routine Practice: Multisite Study of Digital Breast Tomosynthesis and Digital Mammography Screenings

 

Ready to unlock a smarter approach to evidence generation?

OM1 Aspen

  • This field is for validation purposes and should be left unchanged.